Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
Change company Symbol lookup
Select an option...
CYTHW Cyclo Therapeutics Equity Warrants Exp 14th Nov 2025 *W EXP 12/11/2025
FR First Industrial Realty Trust Inc
PNI PIMCO New York Municipal Income Fund II
NIB iPath? Bloomberg Cocoa Subindex Total Return(SM) ETN
DG Dollar General Corp
SPCO Stephan Co
KEX Kirby Corp
GM General Motors Co
F Ford Motor Co
MSFT Microsoft Corp
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Cyclo Therapeutics, Inc. is a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. It is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The Company's product lines include Trappsol and Aquaplex. It sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The Company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Closing Price
$0.76
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.78
Day's Low
0.5088
Volume
(Above Average)
Volume:
1,592

10-day average volume:
1,592
1,592

NOV Inc. Stock Rises Tuesday, Outperforms Market

5:11 pm ET May 17, 2022 (MarketWatch)
Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of NOV Inc. (NOV) advanced 3.11% to $18.92 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 2.02% to 4,088.85 and the Dow Jones Industrial Average rising 1.34% to 32,654.59. This was the stock's third consecutive day of gains. NOV Inc. closed $5.14 short of its 52-week high ($24.06), which the company reached on March 8th.

The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Schlumberger Ltd. (SLB) rose 1.92% to $42.95, Baker Hughes Co. (BKR) rose 0.66% to $35.16, and Dril-Quip Inc. (DRQ) rose 3.47% to $30.45. Trading volume (2.8 M) remained 2.0 million below its 50-day average volume of 4.9 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 17, 2022.

	

(END) Dow Jones Newswires

May 17, 2022 17:11 ET (21:11 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.